Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Feb 22;6(4):1278-1295.
doi: 10.1182/bloodadvances.2021005335.

Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study

David Martínez-Cuadrón  1   2 , Juan E Megías-Vericat  3 , Josefina Serrano  4 , Pilar Martínez-Sánchez  5 , Eduardo Rodríguez-Arbolí  6 , Cristina Gil  7 , Eliana Aguiar  8 , Juan Bergua  9 , José L López-Lorenzo  10 , Teresa Bernal  11 , Ana Espadana  12 , Mercedes Colorado  13 , Carlos Rodríguez-Medina  14 , María López-Pavía  15 , Mar Tormo  16 , Lorenzo Algarra  17 , María-Luz Amigo  18 , María J Sayas  19 , Jorge Labrador  20 , Juan I Rodríguez-Gutiérrez  21 , Celina Benavente  22 , Lissette Costilla-Barriga  23 , Raimundo García-Boyero  24 , Esperanza Lavilla-Rubira  25 , Susana Vives  26 , Pilar Herrera  27 , Daniel García-Belmonte  28 , María Mar Herráez  29 , Graça Vasconcelos Esteves  30 , Maria I Gómez-Roncero  31 , Ana Cabello  32 , Guiomar Bautista  33 , Amaia Balerdi  34 , José Mariz  35 , Blanca Boluda  1   2 , Miguel Á Sanz  2 , Pau Montesinos  1   2
Affiliations
Clinical Trial

Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study

David Martínez-Cuadrón et al. Blood Adv. .

Abstract

Secondary acute myeloid leukemia (sAML) comprises a heterogeneous group of patients and is associated with poor overall survival (OS). We analyze the characteristics, treatment patterns, and outcomes of adult patients with sAML in the Programa Español de Tratamientos en Hematología (PETHEMA) registry. Overall, 6211 (72.9%) were de novo and 2310 (27.1%) had sAML, divided into myelodysplastic syndrome AML (MDS-AML, 44%), MDS/myeloproliferative AML (MDS/MPN-AML, 10%), MPN-AML (11%), therapy-related AML (t-AML, 25%), and antecedent neoplasia without prior chemotherapy/radiotherapy (neo-AML, 9%). Compared with de novo, patients with sAML were older (median age, 69 years), had more Eastern Cooperative Oncology Group ≥2 (35%) or high-risk cytogenetics (40%), less FMS-like tyrosine kinase 3 internal tandem duplication (11%), and nucleophosmin 1 (NPM1) mutations (21%) and received less intensive chemotherapy regimens (38%) (all P < .001). Median OS was higher for de novo than sAML (10.9 vs 5.6 months; P < .001) and shorter in sAML after hematologic disorder (MDS, MDS/MPN, or MPN) compared with t-AML and neo-AML (5.3 vs 6.1 vs 5.7 months, respectively; P = .04). After intensive chemotherapy, median OS was better among patients with de novo and neo-AML (17.2 and 14.6 months, respectively). No OS differences were observed after hypomethylating agents according to type of AML. sAML was an independent adverse prognostic factor for OS. We confirmed high prevalence and adverse features of sAML and established its independent adverse prognostic value. This trial was registered at www.clinicaltrials.gov as #NCT02607059.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Consolidated Standards of Reporting Trials (CONSORT) diagram for secondary AML adult patients.
Figure 2.
Figure 2.
Description of disorders diagnosed before AML. (A) Type of previous MDS in patients included in MDS-AML group. Patients with nonspecified and unclassifiable MDS were not included in this figure. (B) Type of previous MDS/MPN in patients included in MDS/MPN-AML group. (C) Type of previous MPN in patients included in MPN-AML group. (D) Type of previous therapy in patients included in t-AML group. (E) Type of previous neoplasm in treated patients included in t-AML group. (F) Type of previous solid neoplasm in patients with cancer antecedents without prior treatment.
Figure 3.
Figure 3.
OS of the AML patients included in the study according to different disease characteristics or therapeutic approach. (A) OS in the entire cohort of 8521 patients with AML according to type of AML (P < .001). (B) OS in secondary AML according to therapeutic approach (P < .001). (C) OS in secondary AML according to cytogenetic risk (P < .001). (D) OS in secondary AML according to NPM1 mutation (P < .001). (E) OS in secondary AML according to FLT3-ITD mutation (P = .45). (F) OS in secondary AML according to the different subgroups (P = .04).
See this image and copyright information in PMC

References

    1. Leone G, Mele L, Pulsoni A, Equitani F, Pagano L. The incidence of secondary leukemias. Haematologica. 1999;84(10):937-945. - PubMed
    1. Arber DA, Orazi A, Hasserjian R, et al. . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. - PubMed
    1. Granfeldt Østgård LS, Medeiros BC, Sengeløv H, et al. . Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33(31):3641-3649. - PubMed
    1. Hulegårdh E, Nilsson C, Lazarevic V, et al. . Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015;90(3):208-214. - PubMed
    1. Szotkowski T, Rohon P, Zapletalova L, Sicova K, Hubacek J, Indrak K. Secondary acute myeloid leukemia: a single center experience. Neoplasma. 2010;57(2):170-178. - PubMed

Publication types

Associated data